secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001682852-23-000038
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q3 net loss $3.6B on $1.8B revenue; guides 2024 sales ~$4B, aims for 2026 breakeven
--------------------------------------------------------------------------------

- Q3 revenues $1.8B, down 44% YoY; net loss $3.6B vs net income $1.0B; diluted EPS -$9.53.
- Non-cash charges of $3.1B: $1.3B inventory write-downs, $0.5B contract manufacturing wind-down, $1.7B tax valuation allowance.
- 2023 product sales guidance at least $6B; 2024 sales projected ~$4B; expects breakeven in 2026.
- COVID-19 U.S. market share rose to 45% (from 36%); RSV vaccine BLA filed with FDA, launch expected 2024.
- Cash and investments $12.8B; plans to fund without raising equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000038/0001682852-23-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000038/mrna-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001682852-23-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer